NextCure, Inc.
NXTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $41 | $48 | $54 | $50 |
| G&A Expenses | $16 | $20 | $22 | $21 |
| SG&A Expenses | $16 | $20 | $22 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $0 | $0 |
| Operating Expenses | $60 | $68 | $76 | $71 |
| Operating Income | -$60 | -$68 | -$76 | -$71 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $5 | $1 | $1 |
| Pre-Tax Income | -$56 | -$63 | -$75 | -$69 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$56 | -$63 | -$75 | -$69 |
| % Margin | – | – | – | – |
| EPS | -23.88 | -27.039 | -32.324 | -30.152 |
| % Growth | 11.7% | 16.3% | -7.2% | – |
| EPS Diluted | -23.88 | -27.039 | -32.324 | -30.152 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $4 | $4 | $4 |
| EBITDA | -$54 | -$64 | -$72 | -$67 |
| % Margin | – | – | – | – |